Abstract: Ossifying fibromyxoid tumor (OFMTs) of soft parts is a rare soft tissue and bone tumor of borderline malignancy displaying an uncertain line of differentiation. The existence of fully malignant OFMT is controversial. To better understand the natural history and line of differentiation taken by OFMT, we studied 46 cases by light microscopic, immunohistochemical (IHC), genomic, proteomic, and fluorescence in situ hybridization (FISH) methods. Cases were classified according to the 2003 Folpe and Weiss system. Clinical and follow-up information was obtained. IHC for S-100 protein, desmin, epithelial membrane antigen (EMA), cytokeratins, smooth muscle actin (SMA), INI-1, neurofilament protein (NFP), CD56d excitatory amino acid transporter-4 (EAAT4), and MUC4 was performed on formalinfixed, paraffin-embedded (FFPE) tissues. Gene expression profiling and proteomic studies were conducted on FFPE tissues from 13 and 5 cases, respectively. FISH for INI-1 was performed on 10 cases. The 46 tumors arose in 29 men and 17 women (median age, 52 y; range 39 to 63 y) and involved the proximal (N = 17) and distal extremities (N = 13), head and neck (N = 9), and trunk (N = 5). Median tumor size was 5.4 cm (range, 1.0 to 21.0 cm). Cases were classified as typical OFMT (26 of 46, 57%), atypical
O ssifying fibromyxoid tumor (OFMTs) of soft parts, first described by Enzinger et al 10 in 1989, is a rare soft tissue and bone tumor displaying an uncertain line of differentiation. In its classical form, OFMT is characterized by subcutaneous location, a peripheral shell of woven bone, and a vaguely lobular proliferation of small, bland round cells with very low mitotic activity, embedded in a fibromyxoid matrix. 10 Although most OFMTs conform to this morphologic description and show correspondingly benign clinical behavior, it has been recognized for some time that a subset of OFMTs displays atypical cytoarchitectural features, such as high cellularity or elevated mitotic activity, and shows correspondingly more aggressive clinical behavior. 13, 18, 39 Under the risk stratification system proposed in 2003 by Folpe and Weiss, 13 OFMTs are classified as "typical," "atypical," or "malignant" on the basis of their size, nuclear grade, cellularity, and mitotic activity. However, this risk stratification system is not universally accepted, with some investigators, for example, suggesting that morphologically and clinically malignant OFMTs do not exist, representing instead other tumor types. 21 The precise line of differentiation taken by OFMTs has also remained controversial. Enzinger et al, 10 in their original description, noted OFMTs to have ultrastructural features suggestive of incomplete schwannian and/or cartilaginous differentiation. Subsequent immunohistochemical (IHC) studies have also for the most part supported the concept of schwannian differentiation in OFMTs, 13, 16, 20, 29, 30, 39 although myoepithelial differentiation has also been suggested. 18, 22 Given these uncertainties, further study of these rare soft tissue tumors is clearly in order. We therefore undertook a comprehensive study of a large series of well-characterized OFMTs, retrieved from the institutional and consultation files of Mayo Clinic, with the goals of: (1) further elucidating the natural history of OFMT; (2) reassessing the validity of the Folpe and Weiss classification scheme for OFMT; (3) clarifying the line of differentiation taken by OFMT through comprehensive IHC study, gene expression profiling, and proteomic study; and (4) identifying potential new markers of this rare tumor.
MATERIALS AND METHODS
Approval for this study was granted by the institutional review boards of the participating institutions. All available slides for 54 Mayo Clinic internal and consultation cases previously diagnosed as "OFMT" for the period 1998 to 2010 were retrieved and rereviewed by 2 of the authors (R.P.D.G. and A.L.F.). After the rereview, 8 cases were felt to represent something other than OFMT and were excluded, leaving a final study population of 46 cases. Cases previously diagnosed as "malignant" OFMT were included only if clear areas of morphologically "typical" OFMTs were present. S-100 protein expression by the tumor was not required for inclusion in the final study population. Demographic and clinical follow-up information was obtained from the Mayo Clinic medical records and from contributing pathologists and clinicians. All cases were reclassified as "typical," "atypical," and "malignant" according to the previously published criteria of Folpe and Weiss. 13 In brief, this classification system defines typical OFMTs as those showing low nuclear grade and low cellularity and mitotic rate <2/50 high-power fields (HPF). In contrast, malignant OFMTs show high nuclear grade or high cellularity and mitotic activity >2/ 50 HPF. Atypical OFMTs deviate from typical OFMTs but fail to meet criteria for malignancy. Tumors showing foci of nuclear crowding with loss of intervening matrix, occupying at least one 4x microscopic field, were considered to show high cellularity.
IHC for all markers except MUC4 was performed at Mayo Clinic, using 4-micron-thick formalin-fixed, paraffin-embedded (FFPE) tissue sections and commercially available antibodies directed against S-100 protein (polyclonal, 1:50-1:100, Dako Corp, Carpinteria, CA), desmin (DE-R-11, 1:50-1:100, Novocastra, Newcastle upon Tyne, UK), epithelial membrane antigen (E29, 1:50-1:00, Dako Corp.), cytokeratins (OSCAR, 1: 40, Signet, Dedham, MA), smooth muscle actin (SMA) (1A4, 1:100, Dako Corp.), and INI-1 (clone 25, 1:40, BD Transduction Laboratories, Franklin Lakes, NJ). Following our DNA microarray results suggesting expression of neuron-related genes in OFMT (see Results, below), subsets of cases were evaluated for expression of neurofilament protein (2F11, 1:100, Dako Corp.), CD56 (123C3, 1:25, Dako Corp.), and excitatory amino acid transporter-4 (EAAT4), a protein normally expressed in cerebellar Purkinje cells (goat polyclonal, 1:100, Santa Cruz, Santa Cruz, CA). Steam heat-induced epitope retrieval and the Dako Envision detection system (Dako Corp., Carpinteria, CA) were used. MUC4 IHC was performed at the University of Nebraska, using previously published methods. 32 Appropriate positive and negative controls were used. The IHC results were scored as "negative" (no positive cells), "rare" (<5% of cells positive), "1+" (5% to 25% cells positive), "2+" (26% to 50% positive), and "3+" (>50% positive).
Gene microarray study was conducted at UCLA on FFPE blocks from 13 OFMTs (8 typical and 5 malignant). Tumors were macrodissected, and microarray was performed using previously published and validated methods. 31 Total ribonucleic acid (RNA) was isolated using the Ambion RecoverAll (Applied Biosystems/ Ambion, Austin, TX) kit according to the manufacturer's instructions. RNA integrity was evaluated using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA), and purity/concentration was determined using NanoDrop 8000 (NanoDrop Products, Wilmington, DE). Microarray targets were prepared using the NuGEN WT-Ovation Formalin-Fixed Paraffin-Embedded RNA Amplification System and the FL-Ovation complementary DNA Biotin Module V2 (NuGEN Technologies, San Carlos, CA) and then hybridized to the Affymetrix GeneChip U133 Plus 2.0 Array (Affymetrix), all according to manufacturers' instructions. The arrays were washed and stained with streptavidin phycoerythrin in Affymetrix Fluidics Station 450 using the Affymetrix GeneChip protocol and then scanned using an Affymetrix GeneChip Scanner 3000. The acquisition and initial quantification of array images were conducted using AGCC software (Affymetrix). The subsequent data analyses were performed using Partek Genomics Suite Version 6.4 (Partek, St Louis, MO). Cluster analysis and principal component analysis were conducted with Partek default settings. Biofunctional analysis was performed using Ingenuity Pathways Analysis Software Version 7.6 (Ingenuity Systems, Redwood City, CA). The results were compared with previously obtained data from nerve sheath myxomas and schwannoma. 31 Thereafter, typical and malignant OFMTs were compared with each other. Differentially expressed genes were selected at Z5-fold and P<0.005.
Proteomic studies were conducted at Mayo Clinic. For proteomic studies, areas of tumor were microdissected from FFPE sections using laser microdissection microscopy, followed by trypsin digestion, nano-flow liquid chromatography, electrospray ionization, and tandem mass spectrometry (MS/MS) as previously described. 27, 35 The MS/MS data were correlated with known theoretical fragmentation patterns of tryptic peptide sequences from the Swissprot database using the Scaffold algorithm. 35 Molecular cytogenetic studies with fluorescence in situ hybridization (FISH) were conducted on 10 cases of typical OFMTs at St. Jude Children's Research Hospital on 4-mm FFPE tissue sections using a laboratory-developed dual-color probe containing INI-1 (CTD-2511E13+CTD-2034E7) (22q11.2) (orange fluorochrome) probe as the target probe and PANX2 (RPCI3-402G11) (22q13.33) (green fluorochrome) probe as the control. The paraffin-embedded tissue was pretreated in a 601C oven for 30 minutes, deparaffinized in xylene/isopropanol, and pressure-cooked in a citrate buffer for 60 minutes. The tissue was digested by placing the slide in a coplin jar containing 4 mg/mL of pepsin at 371C for 3 to 5 minutes, depending on the tissue density. The probes were codenatured with target DNA at 901C for 12 minutes on a ThermoBrite slide processing system and hybridized at 371C for 24 hours. After hybridization, the slides were washed and counterstained with DAP1-Vectashield mounting solution (Vector). Hybridization signals were analyzed with an Olympus epifluorescence microscope equipped with Applied Imaging software. By in-house validation studies, cut-off values of 41%, 23%, and 9% were established for loss of 1 copy of 22q, for hemizygous deletion of SMARCB1 (INI-1), and for homozygous deletion of SMARCB1 (INI-1), respectively.
RESULTS

Clinical and Microscopic Features, Including Clinical Follow-Up
The 46 tumors arose in 29 men and 17 women, with a median age of 52 years (range, 39 to 63 y). The tumors arose predominantly in the soft tissues of the proximal (N = 17) and distal extremities (N = 13) but also involved the head and neck (N = 9) and the trunk (N = 5). The median tumor size was 5.4 cm (range, 1.0 to 21.0 cm). Radiographically, the tumors appeared as nonspecific soft tissue masses, on occasion showing surrounding or intralesional calcification on plain radiographs or computed tomographic scans. Grossly, the tumors were generally well circumscribed, occasionally had a visible shell of bone, and showed a vaguely lobulated appearance with a gritty cut surface.
By definition, all tumors showed, at least in part, classical morphologic features of OFMT as previously described (Fig. 1) . 10, 13 A partial shell of woven bone was present in 29 of 48 (60%) cases, including 19 of 26 (73%) typical, 3 of 5 (60%) atypical, and 7 of 15 (47%) Ossifying Fibromyxoid Tumor malignant OFMTs. In brief, typical OFMTs (26 of 46 cases, 57%) were composed of a low to at the most moderately cellular proliferation of very bland, uniform, round-to-slightly ovoid cells embedded in a myxoid, fibromyxoid, or hyalinized stroma. Mitotic activity was <2/50 HPF; necrosis and vascular space invasion were absent. In addition to areas of typical OFMTs, malignant OFMTs (15 of 46 cases, 32%) contained areas showing a combination of high nuclear grade, high cellularity, and mitotic activity >2/50 HPF. 13 Necrosis and infiltrative growth were seen in subsets of malignant cases. Histologically, malignant foci could be identified at the time of initial presentation (13 of 15 cases, 87%) (Fig. 2) or in subsequent local recurrences of initially typical OFMTs (2 of 15 cases, 13%) (Fig. 3) . Five of 46 cases (11%) were classified as atypical OFMT.
The clinical follow-up data are summarized in Table 1 . Clinical follow-up was available for 27 cases (59%), with a median of 55 months' duration (range, 12 to 149 mo). All patients with typical OFMT were alive without disease at the time of last clinical follow-up. Similarly, both patients with atypical OFMT with followup were disease free at the time of the last clinical contact. In contrast, adverse events were seen in 33% of patients with malignant OFMT with follow-up, including 2 patients with local recurrences (3 events), 3 patients with distant metastases, and 3 deaths from disease. One patient with a malignant OFMT is known to be alive with persistent disease.
IHC Results
The IHC results are summarized in Table 2 . In agreement with previous studies, expression of S-100 protein was seen in the majority of studied cases (30 of 41 cases, 73%), including 88% of typical, 75% of atypical, and 42% of malignant OFMTs. S-100 protein expression was typically present at 1 to 2+ and was seldom diffusely positive (Fig. 4A) . Malignant OFMTs typically showed FIGURE 2. Malignant OFMT, "de novo" type. This tumor arose in the groin of a middle-aged man and showed a shell of woven bone on computed tomographic scan (A). At scanning magnification, areas of hypocellular typical OFMT are juxtaposed to areas showing greater cellularity and nuclear enlargement (B). At higher-power magnification, the malignant areas of this tumor showed high nuclear grade and mitotic activity. Note shell of woven bone (C). This patient suffered multiple pleural and pulmonary metastases and died of disease (D).
greater S-100 protein expression in typical, as compared with malignant-appearing, areas. Anomalous desmin expression was also relatively common, present in 15 of 39 (38%) cases, including 43% of typical, 50% of atypical, and 25% of malignant tumors (Fig. 4B) . Cytokeratin, epithelial membrane antigen, and SMA expressions were seen in only a small number of cases, typically at 1+. Loss of INI-1 expression in 30% to 60% of lesional cells ("mosaic pattern") was noted in 14 of 19 (74%) tested cases (Fig. 4C) .
After the identification of EAAT4 and MUC4 overexpression by DNA microarray (see Gene Expression Profiling Results, below), subsets of OFMT were tested for EAAT4 and MUC4 expression. Patchy (1 to 2+) EAAT4 expression was noted in 31 of 39 (80%) tested cases (Fig. 4D) . MUC4 was positive in 3 of 14 (21%) tested cases (Fig. 4E) . Focal (1+) expression of other neuron-associated markers, neurofilament protein and CD56, was present in 80% and 43% of cases, respectively (Fig. 4F, G) .
Gene Expression Profiling Results
The gene expression profiling results, comparing typical OFMT with schwannoma and nerve sheath myxoma, are illustrated in a Venn diagram (Fig. 5A) , a cluster map (Fig. 5B) , and in a principal component analysis map (Fig. 5C ). As shown in the Venn diagram, OFMTs show >1000 differentially expressed genes, as compared with nerve sheath myxomas and schwannomas, tumors that were previously shown to have similar expression profiles. 31 The differences between OFMT and nerve sheath myxoma/schwannoma are further illustrated in the cluster and principal component analyses, showing OFMT to clearly segregate from the latter 2 entities. Selected genes that are upregulated and downregulated in OFMT as compared with nerve sheath myxoma/schwannoma are listed in Table 3 . Of the upregulated genes, EAAT4 is normally expressed principally by neuronal cells, whereas the remainder of this group does not show tissue restriction. Figure 5D illustrates relative EAAT4 expression levels in OFMT as compared with schwannoma and nerve sheath myxoma. The 2 downregulated genes listed, peripheral myelin protein 22 (PMP22) and myelin expression factor 2 (MYEF2), are both typically expressed in Schwann cells. Figure 5E illustrates relative PMP22 expression levels in OFMT as compared with schwannoma and nerve sheath myxoma. A very large number (>1000) of other genes, without known tissue restriction, were also downregulated in OFMT as compared with schwannian tumors (data not shown). Importantly, no significant differences in gene expression profiles were noted between typical and malignant OFMTs, supporting the relationship of these 2 groups of tumors.
Proteomic Results
Mass spectrometry-based proteomic analysis identified a total of 896 unique proteins in the 5 tumor samples studied (Fig. 6 ). These included a large number of matrix proteins in OFMT, including collagens types 1A1, 1A2, and 6A3. Type 2 collagen (COL2A1), associated with cartilage and cartilage-producing tumors, was present in 2 of 5 cases studied. Other proteins identified in abundance included members of the family of S-100 proteins, versican (a neuron-associated glycoprotein), katanin (a neuron-associated microtubule severing protein), and numerous histones.
FISH Results
All cases studied with FISH were known to show "mosaic" pattern INI-1 expression by IHC. Seven of the 10 tested cases underwent successful hybridization; in 2 cases the FISH test showed a normal signal pattern distribution, and the other 5 had an abnormal signal pattern (Table 4 ). These 5 cases had hemizygous deletion of INI-1 and PANX2 (the control probe) in a significant population of cells (43% to 89%; mean, 65%) (Fig. 7A) . Of interest, in 3 of these cases, an additional abnormal population was identified, showing 2 signals for INI-1 and 1 signal for the control, consistent with the loss of the telomeric region of 22q in 1 chromosome without INI-1 deletion (Fig. 7B) .
DISCUSSION
This study was designed to address a number of questions about OFMT, the first (and perhaps most important) of which is: "Do malignant OFMTs exist, and, if so, can we reliably recognize them?" We believe that our study answers both of these questions in the affirmative. In our opinion, histologically malignant OFMTs clearly exist. Such tumors are defined by the presence of clear-cut areas of morphologically typical OFMTs juxtaposed to areas showing high nuclear grade, high cellularity, and elevated mitotic activity, while maintaining the overall cytoarchitectural features of OFMT (eg, lobularity, fibromyxoid matrix, uniform cell-cell spacing, and nonpleomorphic round-to-ovoid cells). Indeed, we have yet to see a completely convincing example of histologically malignant OFMTs in which areas of ordinary OFMTs were not present, either in the primary tumor or (even more convincingly) in an earlier presentation.
The relationship between typical and malignant OFMTs is also supported by our gene expression (26) profiling and IHC data. We observed very similar expression profiling patterns in both typical and malignant OFMTs when compared with nerve sheath myxoma/ schwannoma (eg, upregulation of EAAT4 and MUC4 and downregulation of PMP22 and MYEF2), nor did we observe any significant differences when typical and malignant OFMTs were directly compared. Immunohistochemically, typical and malignant OFMTs showed roughly similar frequency of expression of the various markers tested, albeit with diminished expression of S-100 protein in malignant OFMT and an increased frequency of focal, weak expression of epithelial markers (eg, cytokeratins and epithelial membrane antigen). Diminished S-100 protein expression in malignant OFMTs likely reflects malignant progression in neoplastic cells, akin to the diminished CD34 expression that often accompanies fibrosarcomatous transformation in dermatofibrosarcoma protuberans. 1 In particular, we believe that our finding of a "mosaic" pattern of INI-1 protein loss in identical percentages of typical and malignant OFMTs (discussed further, below) argues persuasively in favor of their relationship, as this is a highly unusual pattern of INI-1 protein expression previously reported only in rare schwannomas associated with familial schwannomatosis 26 and in some synovial sarcomas. 19 Obviously, different results would be expected if malignant OFMTs represented instead other sarcoma types.
Given our results, we believe that the previous suggestion by Miettinen et al, 21 which states that histologically and clinically malignant OFMTs do not exist, reflects their arbitrary definition of OFMT as a tumor without atypical features.
Our data support the validity of the risk stratification system for OFMT proposed initially by Folpe and Weiss in 2003, 13 inasmuch as we observed clinically malignant behavior (eg, aggressive local recurrences and distant metastases) only in tumors fulfilling criteria for malignant OFMT. The relatively high percentage of malignant OFMTs (32%) in this study likely reflects the unique nature of our consultation practice. We did not observe any metastases in cases classified as typical or atypical OFMT, although metastases have been previously documented in 4% and 6% of cases falling into those categories, respectively. 13 Metastases were not observed in typical OFMTs studied by Miettinen et al, 21 although local recurrences were present in 22% of patients with follow-up. Clinically, malignant behavior in OFMTs has also been documented in several other small studies, typically in cases showing histologic features suggestive of malignancy. 18, 24, 28, [37] [38] [39] Putting together the results of this study with those of earlier studies, it is likely that the metastatic risk of typical OFMT is <5%, supporting the current World Health Organization classification of OFMT as an "intermediate (rarely metastasizing)" mesenchymal tumor.
12 Cases fulfilling criteria for malignant OFMT should, however, be regarded as high-grade sarcomas.
Turning to the question of the line of differentiation taken by OFMT, our data suggest that OFMTs show a "scrambled" phenotype, with limited expression of schwannian and cartilaginous markers, as previously noted, as well as expression of a variety of neural markers, a novel finding. Although schwannian differentiation has generally been favored in OFMTs on the basis of ultrastructural findings such as the presence of well-developed, occasionally reduplicated external lamina and S-100 protein expression, 8, 11, 16, 20 our gene expression data do not support this conclusion. By both cluster analysis and principal component analysis, OFMTs were clearly distinct from nerve sheath myxoma and schwannoma; both highly differentiated schwannian neoplasms. Expression of some Schwann cell-related genes, such as PMP22 and MYEF2, was in fact downregulated in OFMT as compared with nerve sheath myxoma/schwannoma. Cartilaginous differentiation has also been suggested in OFMT, on the basis of ultrastructural features such as irregular cell borders with short processes and intracellular microfilaments and S-100 protein expression. 10 Although we were not able to compare OFMTs with cartilaginous tumors by gene expression profiling, we did identify collagen II production in 2 of 5 cases studied by proteomic methods, suggesting that at least some OFMTs may show limited cartilaginous differentiation. S-100 protein expression in OFMTs, shown in this study by both proteomic study and IHC, might also suggest some element of schwannian or cartilaginous differentiation in these tumors, although a wide variety of nonschwannian/noncartilaginous cell types may express S-100 protein. 36 Finally, our findings of only very infrequent cytokeratin or SMA expression would seem to offer little support for the notion of myoepithelial differentiation in OFMTs.
Surprisingly, we found OFMTs to express some neuron-associated genes and proteins by gene expression profiling, proteomic study, and IHC. DNA microarray identified a neuron-associated gene, EAAT 4, to be expressed at high levels in OFMT as compared with schwannian tumors. EAAT4 is a member of the highaffinity glutamic acid and neutral amino acid transporter family, expressed principally in the cerebellar cortex. 7, 14 We were able to confirm EAAT4 protein expression in 80% of OFMTs by IHC. Our microarray data also identified another neuron-related gene, HuC, as being overexpressed at a 4-fold to 5-fold level, with a highly significant P value (data not shown). However, we were not able to identify a HuC antibody applicable to FFPE 2 and versican, a neuron-associated proteoglycan, 3 in tested cases of OFMT. Although it is obviously premature to ascribe neuronal differentiation to OFMT, in the absence of any convincing light microscopic or ultrastructural supporting evidence, these findings are intriguing. Conceivably, OFMTs may be showing limited, aberrant expression of neuronal markers because of yet to be defined, dysregulating, upstream genetic events. The significance of expression of MUC4, a mucin-related protein expressed by various epithelia, in OFMT is obscure.
INI-1 is a putative tumor suppressor gene located on chromosome 22q11.2 that encodes a protein that is expressed essentially in all nucleated cells. Homogeneous loss of immunoreactivity has been identified in most cases of epithelioid sarcoma, 6, 17, 25 atypical teratoid rhabdoid tumor, 4, 5 rhabdoid tumor of the kidney, and malignant extrarenal rhabdoid tumor, 33 with mutations of INI-1 thought to play a pathogenetic role in tumorigenesis. 23, 34 As noted above, we observed an unusual loss of INI-1 protein expression in 30% to 60% of neoplastic cells ("mosaic pattern"), a finding previously reported only in schwannomas associated with familial schwannomatosis and in some synovial sarcomas. 19, 26 Our FISH studies for INI-1 suggest that 22q may carry genes with some possible pathogenic relevance in this tumor. Most examined cases showed aneuploidy for chromosome 22 in a significant population of cells, suggesting a possible pathogenic role for INI-1 in OFMT. Although none of the 7 cases we evaluated were found to have a homozygous deletion for INI-1, 5 cases showed a hemizygous deletion of both INI-1 and PANX2 (the control probe) on average in >50% of cells, and 3 of the 5 had a second population of cells showing 2 signals for INI-1 and 1 signal for the control, suggesting loss of 1 copy of the 22q telomeric region. However, the molecular events leading to the loss of expression in a subpopulation of tumor cells are unclear. In the heterozygous state for the gene deletion, we hypothesize that epigenetic events such as posttranslational modifications, or genetic aberrations that are not detectable by FISH, such as small deletions or mutations, could contribute to the loss of function of the INI-1 on the intact chromosome. In contrast, the finding of a second existing population of cells with the loss of distal 22q without INI-1 loss raises the possibility that other genes in this chromosomal region, such as the NF2 gene, implicated in neurofibromatosis type II, 15 may play a crucial role in the pathogenesis of OFMT. In any event, we have been able to confirm aneuploidy for the long arm of chromosome 22 in a subset of tested cases, strongly suggesting a role for INI-1 or for an adjacent locus in the pathogenesis of OFMT. Interestingly, mosaic pattern loss of INI-1 was seen both in morphologically and clinically typical OFMTs and in malignant OFMTs. No difference in behavior was noted in tumors showing retained INI-1 expression compared with those with mosaic pattern INI-1 loss. We are not aware of any reports of OFMT arising in the setting of familial INI-1 or NF2 gene mutations, nor were such histories present in any of our cases.
In conclusion, we believe that the results of our study amply confirm the existence of malignant OFMT and also the validity of the current risk stratification system for OFMT. Although the line of differentiation taken by this rare tumor remains enigmatic, expression of neuron-related markers in OFMT appears to be significantly more common compared with expression of schwannian or cartilaginous markers. The significance of expression of neuronal markers in OFMT remains to be fully elucidated. EAAT4 may prove to be a novel diagnostic marker of use in the differential diagnosis of OFMT, although study of large numbers of potential OFMT mimics is required before these can be recommended. MUC4 is unlikely to be a useful marker of OFMT, particularly because it is known that MUC4 is frequently expressed in at least 1 potential mimic of OFMT, low-grade fibromyxoid sarcoma. 9 The role of INI-1 loss and 22q aneuploidy in OFMT also warrants further study.
